The FDA has accepted Rybrevant Faspro (amivantamab and hyaluronidase-lpuj) as the primary and solely subcutaneous, chemo-free therapy for sufferers with EGFR-mutated non-small cell lung most...
Lively Biotech has obtained optimistic suggestions from regulators on a protocol modification to its ongoing proof-of-concept scientific trial evaluating tasquinimod in sufferers with myelofibrosis, a...
Lengthy-term outcomes from the CATNON trial confirmed that including adjuvant temozolomide after radiotherapy considerably improved survival for sufferers with newly recognized IDH-mutant,...
In an interview for CURE Educated Affected person® Updates, Drs. Alexandra Miller, Daniel Orringer and Jonathan Yang mentioned how understanding analysis, biomarker...
Dr. Graeme M. Rosenberg, a thoracic surgeon specializing in airway intervention and reconstruction, and Dr. Jorge J. Nieva, an affiliate professor of...
